Processa Pharma Shares Jump Premarket After Expansion of NGC-Cap Program
20 January 2024 - 12:39AM
Dow Jones News
By Chris Wack
Processa Pharmaceuticals shares were up 60% to 32 cents in
premarket trading after the company said it plans to expand the
development of Next Generation Capecitabine, or NGC-Cap, into a
treatment of advanced or metastatic breast cancer beginning with
its next Phase 2 trial.
The move follows Processa's meeting with the U.S. Food and Drug
Administration, with Processa deciding the next NGC-Cap trial would
be a Phase 2 trial in breast cancer.
This decision was supported through discussions with the FDA
where Processa agreed with the FDA that pursuing breast cancer will
lead to a more efficient development program while providing a
greater likelihood of FDA approval.
The FDA stated that the previously generated data in past and
existing studies could be used to directly support the Phase 2
trial in breast cancer.
The company plans to begin its Phase 2 study in the third
quarter of 2024.
Processa said the NGC-Cap potential market for breast,
colorectal and other cancers is greater than 250,000 patients per
year.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 19, 2024 08:24 ET (13:24 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.